Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 1.00 |
| ▸ | HTR3A | P46098 | 5/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29694104 | 0.98 | HRH4 (0.97) | HRH4HTR3AHTR3BMEN1KMT2A | |
| SCHEMBL29268331 | 0.94 | HRH4 (0.88) | HRH4HTR3AHTR3BMEN1KMT2A | |
| SCHEMBL14513387 | 0.91 | HRH4 (0.83) | HRH4HTR3AHTR3BMEN1KMT2A | |
| SCHEMBL5774076 | 0.84 | HRH4 (0.72) | HRH4HTR3AHTR3B | |
| SCHEMBL5772481 | 0.84 | HRH4 (0.72) | HRH4HTR3AHTR3B | |
| SCHEMBL404202 | 0.83 | HRH4 (0.70) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL27661218 | 0.83 | HRH4 (0.70) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL30223251 | 0.83 | HRH4 (0.73) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL405806 | 0.83 | HRH4 (0.73) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL24970254 | 0.82 | HRH4 (0.69) | HRH4HTR3AHTR3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| CN-1886389-B | Quinoxaline compounds | JANSSEN PHARMACEUTICA NV | 2010-07-21 | — | — | CN | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
| CN-1886389-A | Quinoxaline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 137/4885HTR3B 122/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 153/4885HTR3B 113/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 153/4885HTR3B 113/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | HRH4 1290/4885HTR3A 4393/4885HTR3B 4487/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 153/4885HTR3B 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.